GenSure
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese IVD company developing and manufacturing CE-marked rapid test kits and quantitative assays for infectious diseases, fertility, and tropical diseases.
Oncology
Technology Platform
Core technologies include lateral flow immunoassay for rapid qualitative tests and fluorescence immunoassay (FIA) for quantitative analysis, with a focus on developing multi-pathogen combination panels.
Opportunities
Growth opportunities include leveraging new EU IVDR certifications to expand in European markets, increasing demand for at-home and multiplex infectious disease testing, and potential expansion into oncology diagnostics as per its stated category.
Risk Factors
Key risks include intense competition in the generic rapid test market, pricing pressure, regulatory hurdles associated with the ongoing IVDR transition in the EU, and reliance on the infectious disease segment which can be cyclical.
Competitive Landscape
GenSure competes with numerous global and Chinese IVD companies like Abbott, Roche, BioMerieux, and BioSino in the rapid test and FIA segments. Its differentiation lies in cost-effective, scalable manufacturing, a broad portfolio of CE-marked combo panels, and flexible OEM/ODM services.